In a first-of-its-kind reveal, Novartis has presented histology data for iscalimab (CFZ533) at the American Transplant Congress (ATC) which indicates that the drug may be able to extend the survival of transplanted kidneys and improve the long-term outcomes of kidney transplant patients.
The findings showed that calcineurin-free treatment with iscalimab resulted in lower chronic allograft damage index (CADI) scores compared to current standard of care tacrolimus, with three of five trial participants displaying normal renal histology, compared to none of the seven tacrolimus patients.
![Het beste uit je content halen met een kloppend verhaal [10 stappen]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/businesswoman-working-at-creative-office-2023-11-27-05-24-05-utc-1-80x60.jpg)
